A study to investigate the safety and efficacy of SAR446523 injected subcutaneously in adult participants with relapsed/refractory myeloma

Trial Identifier: TED18162
Sponsor: Sanofi
Start Date: October 2024
Primary Completion Date: May 2031
Study Completion Date: May 2031
Condition: Myeloma

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
AUSTRALIA, New South Wales Wollongong, New South Wales, AUSTRALIA, 2500
AUSTRALIA, Victoria Melbourne, Victoria, AUSTRALIA, 3065
CANADA, British Columbia Vancouver, British Columbia, CANADA, V5Z 1L3
CANADA, Quebec MONTREAL, Quebec, CANADA, H4A 3J1
CANADA, Quebec Sherbrooke, Quebec, CANADA, J1H 5N4
FRANCE Lille, FRANCE, 59037
FRANCE Nantes, FRANCE, 44093
ISRAEL Haifa, ISRAEL, 3109601
ISRAEL Jerusalem, ISRAEL, 9112001
ISRAEL, Malopolskie Tel Aviv, Malopolskie, ISRAEL, 6423906
ITALY, Ancona Torette, Ancona, ITALY, 60020
ITALY, Milano Rozzano, Milano, ITALY, 20089
SPAIN, Barcelona [Barcelona] Barcelona, Barcelona [Barcelona], SPAIN, 08035
SPAIN, Madrid Madrid, SPAIN, 28040
UNITED STATES, Arizona Phoenix, Arizona, UNITED STATES, 85054
UNITED STATES, Florida Jacksonville, Florida, UNITED STATES, 32224
UNITED STATES, Minnesota Rochester, Minnesota, UNITED STATES, 55905
UNITED STATES, New Jersey Hackensack, New Jersey, UNITED STATES, 07601
UNITED STATES, Pennsylvania PHILADELPHIA, Pennsylvania, UNITED STATES, 19107